Beximco Pharmaceuticals Limited (BXP.L)
GBp 38.0
(1.33%)
GBp 38.0
(1.33%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 21.53 Billion BDT | 0.12% |
| 2021 | 21.51 Billion BDT | 44.56% |
| 2020 | 14.88 Billion BDT | -14.09% |
| 2019 | 17.32 Billion BDT | -10.48% |
| 2018 | 19.34 Billion BDT | 18.08% |
| 2017 | 16.38 Billion BDT | 81.84% |
| 2016 | 9.01 Billion BDT | 7.84% |
| 2015 | 8.35 Billion BDT | 3.42% |
| 2014 | 8.08 Billion BDT | 5.0% |
| 2013 | 7.69 Billion BDT | 24.48% |
| 2012 | 6.18 Billion BDT | 4.68% |
| 2011 | 5.9 Billion BDT | 9.39% |
| 2010 | 5.39 Billion BDT | -40.06% |
| 2009 | 9 Billion BDT | 106.11% |
| 2008 | 4.36 Billion BDT | 18.02% |
| 2007 | 3.7 Billion BDT | -6.57% |
| 2006 | 3.96 Billion BDT | -3.93% |
| 2005 | 4.12 Billion BDT | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q3 | 19.81 Billion BDT | -8.2% |
| 2023 Q1 | 20.16 Billion BDT | -6.37% |
| 2023 Q2 | 21.58 Billion BDT | 7.04% |
| 2022 Q2 | 23.59 Billion BDT | 10.09% |
| 2022 FY | 21.53 Billion BDT | 0.12% |
| 2022 Q4 | 21.53 Billion BDT | -3.05% |
| 2022 Q3 | 22.21 Billion BDT | -5.83% |
| 2022 Q1 | 21.42 Billion BDT | -0.39% |
| 2021 Q2 | 22.28 Billion BDT | 17.84% |
| 2021 Q3 | 21.31 Billion BDT | -4.37% |
| 2021 Q4 | 21.51 Billion BDT | 0.95% |
| 2021 FY | 21.51 Billion BDT | 44.56% |
| 2021 Q1 | 18.9 Billion BDT | 27.07% |
| 2020 Q4 | 14.88 Billion BDT | -2.92% |
| 2020 Q3 | 15.32 Billion BDT | -8.6% |
| 2020 Q2 | 16.77 Billion BDT | -0.01% |
| 2020 Q1 | 16.77 Billion BDT | -3.16% |
| 2020 FY | 14.88 Billion BDT | -14.09% |
| 2019 Q2 | 17.71 Billion BDT | -1.47% |
| 2019 Q1 | 17.97 Billion BDT | -7.09% |
| 2019 Q4 | 17.32 Billion BDT | -5.02% |
| 2019 Q3 | 18.23 Billion BDT | 2.95% |
| 2019 FY | 17.32 Billion BDT | -10.48% |
| 2018 Q2 | 17.68 Billion BDT | 5.29% |
| 2018 Q1 | 16.79 Billion BDT | 2.5% |
| 2018 Q4 | 19.34 Billion BDT | 10.96% |
| 2018 FY | 19.34 Billion BDT | 18.08% |
| 2018 Q3 | 17.43 Billion BDT | -1.4% |
| 2017 Q3 | 12.48 Billion BDT | 18.89% |
| 2017 Q2 | 10.49 Billion BDT | 19.66% |
| 2017 Q1 | 8.77 Billion BDT | -2.63% |
| 2017 FY | 16.38 Billion BDT | 81.84% |
| 2017 Q4 | 16.38 Billion BDT | 31.27% |
| 2016 Q4 | 9.01 Billion BDT | 5.25% |
| 2016 Q2 | 8.2 Billion BDT | 5.34% |
| 2016 Q3 | 8.56 Billion BDT | 4.42% |
| 2016 Q1 | 7.78 Billion BDT | -3.77% |
| 2016 FY | 9.01 Billion BDT | 7.84% |
| 2015 Q4 | 8.08 Billion BDT | 0.0% |
| 2015 Q1 | 8.48 Billion BDT | -1.0% |
| 2015 FY | 8.35 Billion BDT | 3.42% |
| 2015 Q2 | 8.35 Billion BDT | -1.46% |
| 2014 Q4 | 8.56 Billion BDT | 3.97% |
| 2014 Q3 | 8.23 Billion BDT | 1.97% |
| 2014 Q2 | 8.08 Billion BDT | 0.85% |
| 2014 Q1 | 8.01 Billion BDT | -1.65% |
| 2014 FY | 8.08 Billion BDT | 5.0% |
| 2013 Q1 | 6.05 Billion BDT | 2.09% |
| 2013 Q2 | 7.69 Billion BDT | 26.99% |
| 2013 Q3 | 7.61 Billion BDT | -1.06% |
| 2013 Q4 | 8.14 Billion BDT | 7.01% |
| 2013 FY | 7.69 Billion BDT | 24.48% |
| 2012 Q1 | 6.16 Billion BDT | 0.0% |
| 2012 Q3 | 6.18 Billion BDT | -0.02% |
| 2012 FY | 6.18 Billion BDT | 4.68% |
| 2012 Q4 | 5.93 Billion BDT | -3.97% |
| 2012 Q2 | 6.18 Billion BDT | 0.3% |
| 2011 Q2 | 5.9 Billion BDT | 2.78% |
| 2011 FY | 5.9 Billion BDT | 9.39% |
| 2011 Q1 | 5.74 Billion BDT | 3.08% |
| 2010 Q4 | 5.57 Billion BDT | 1.18% |
| 2010 Q1 | 5.39 Billion BDT | 3.31% |
| 2010 Q2 | 5.39 Billion BDT | 0.07% |
| 2010 Q3 | 5.5 Billion BDT | 2.05% |
| 2010 FY | 5.39 Billion BDT | -40.06% |
| 2009 Q1 | 5.21 Billion BDT | 9.6% |
| 2009 Q4 | 5.22 Billion BDT | -25.07% |
| 2009 Q3 | 6.96 Billion BDT | -22.62% |
| 2009 Q2 | 9 Billion BDT | 72.85% |
| 2009 FY | 9 Billion BDT | 106.11% |
| 2008 Q2 | 4.36 Billion BDT | 0.0% |
| 2008 Q4 | 4.75 Billion BDT | 0.0% |
| 2008 FY | 4.36 Billion BDT | 18.02% |
| 2007 Q2 | 3.7 Billion BDT | 0.0% |
| 2007 FY | 3.7 Billion BDT | -6.57% |
| 2007 Q4 | 3.92 Billion BDT | 0.0% |
| 2006 FY | 3.96 Billion BDT | -3.93% |
| 2005 FY | 4.12 Billion BDT | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|